- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT02859324
A Safety and Efficacy Study of CC-122 in Combination With Nivolumab in Subjects With Unresectable Hepatocellular Carcinoma (HCC)
A Phase 1/2, MultiCenter, Open-label, Dose Finding Study to Assess the Safety, Tolerability and Preliminary Efficacy of CC-122 in Combination With Nivolumab in Subjects With Unresectable Hepatocellullar Carcinoma (HCC) Following First Line Treatment Failure
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
Study population included subjects who had progressed after or were intolerant to no more than 2 previous systemic therapies for unresectable HCC, or are naïve to systemic therapy.
The dose escalation part of the study was designed to explore three dose levels of CC-122 to identify the recommended phase 2 dose (RP2D) to be used in the expansion phase. Approximately 20 subjects were to be enrolled in the dose escalation part of the study. Subjects could be treated for up to 2 years, or until progression of disease, unacceptable toxicity, subject/physician decision, withdrawal of consent, death. Safety follow up until 28 days after CC122 treatment and 90 days after nivolumab treatment. RECIST 1.1 criteria was used to determine response. Survival follow up until death, withdrawal of consent, or the study closes. Subjects were permitted to continue treatment beyond progression (TBP) if they continue to meet protocol criteria, had stable performance status, had clinical benefit, other treatment options were discussed. A separate ICF was signed to continue TBP.
During the dose escalation phase, CC-122 was administered orally 5 consecutive days out of 7 (5 days on/2 days off weekly) on Days 1 to 5, 8 to 12, 15 to 19 and 22 to 26 of each 28-day cycle. Once the RP2D for dosing of CC-122 in combination with nivolumab was defined, expansion (Phase 2) would start. A modified 3+3 dose escalation design was used to identify the initial toxicity of the combination. Up to six subjects were concurrently enrolled into a dose level. Decisions as to which dose level to enroll a new subject were based on the number of subjects enrolled and evaluable, the number of subjects experiencing DLTs, and the number of subjects enrolled but who are not yet evaluable for toxicity in the current cohort at the time of new subject entry. A Safety Review Committee (SRC) comprised of investigators participating in the study made dose escalation decisions based on these criteria.
After completion of the Dose Escalation Phase, the Dose Expansion Phase of the study did not proceed due to the changing landscape in the treatment of HCC. There were no additional safety concerns or safety signals identified in the dose escalation phase of the study.
Tipo de estudo
Inscrição (Real)
Estágio
- Fase 2
- Fase 1
Contactos e Locais
Locais de estudo
-
-
-
Barcelona, Espanha, 8035
- Hospital Universitario Vall D Hebron
-
Madrid, Espanha, 28034
- Hospital Ramón y Cajal
-
Madrid, Espanha, 28041
- Hospital 12 de Octubre
-
-
-
-
California
-
Los Angeles, California, Estados Unidos, 90095-1752
- UCLA Division of Hematology Oncology
-
-
Florida
-
Gainesville, Florida, Estados Unidos, 32610
- University of Florida
-
-
New York
-
New York, New York, Estados Unidos, 10016
- NYU Langone Medical Center
-
-
Texas
-
Dallas, Texas, Estados Unidos, 75251
- Mary Crowley Cancer Research
-
-
-
-
-
Marseille Cedex 9, França, 13273
- Institut Paoli Calmettes
-
Rennes, França, 35200
- Centre Eugene Marquis
-
Toulouse Cedex, França, 31059
- Institut Universitaire du Cancer IUCT - Oncopole
-
Villejuif CEDEX, França, 94805
- Institut Gustave Roussy Hematologie
-
-
-
-
-
Milan, Itália, 20089
- IRCCS - Istituo Clinico Humanitas - Humanitas Cancer Center
-
Pavia, Itália, 27100
- Fondazione Irccs Policlinico San Matteo
-
Roma, Itália, 144
- Istituto Nazionale Tumori Regina Elena
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Subjects must satisfy the following criteria to be enrolled in the study:
- Subject is ≥ 18 years of age at the time of signing the informed consent form (ICF)
- Subject has a confirmed pathologic diagnosis of Hepatocellular carcinoma (HCC) according to the American Association for the Study of Liver Diseases (AASLD) Guidelines.
- Subjects who have progressed after or were intolerant to no more than 2 previous systemic therapies for unresectable HCC, or are naïve to systemic therapy.
- Subject has at least one measurable lesion according to RECIST 1.1.
- Subject has a life expectancy of ≥ 12 weeks
- Subject has an Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1
- Subject has adequate hematologic function and adequate hepatic function at screening
Exclusion Criteria:
- The presence of any of the following will exclude a subject from enrollment:
- Subject has received more than 2 previous systemic therapies for Hepatocellular carcinoma (HCC).
- Subject has received previous treatment with any anti-PD-1 (Programmed death 1) or anti-PD-L1 (PD-1 ligand receptor) antibody
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: N / D
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
---|---|
Experimental: CC-122 with Nivolumab
CC-122 orally 5/7 days with nivolumab Intravenously (IV) 3mg/kg every 2 weeks.
Cohorts of up to 6 subjects per dose level until Recommended Phase 2 dose (RP2D).
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Incidence of Dose Limiting Toxicities (DLTs)
Prazo: 28 days
|
During dose escalation, the DLT assessment period is defined as Days 1 to 28 of Cycle 1 including the predose assessments specified for Day 1 of Cycle 2. A DLT is defined as any of the following toxicities occurring within the DLT assessment window unless the event can clearly be determined to be unrelated to the drug. |
28 days
|
Incidence and Severity of Treatment-Emergent Adverse Events (TEAEs)
Prazo: From first dose up to 28 days (CC-122) or 90 days (nivolumab) post-last dose (up to 2 years)
|
During dose escalation, the TEAE phase 1 assessment period is defined as Days 1 to 28 of Cycle 1 including the predose assessments specified for Day 1 of Cycle 2. Number of participants who experienced a TEAE during the course of the study. |
From first dose up to 28 days (CC-122) or 90 days (nivolumab) post-last dose (up to 2 years)
|
Objective Response Rate (ORR) by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)
Prazo: up to 2 years
|
ORR is is defined as the number and percentage of participants with a best overall response (BOR) of confirmed complete response (CR) or partial response (PR).
|
up to 2 years
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Disease Control Rate (DCR) by RECIST 1.1
Prazo: up to 2 years
|
DCR is is defined as the number and percentage of participants with a best overall response (BOR) of confirmed complete response (CR) or partial response (PR) or stable disease (SD).
|
up to 2 years
|
Duration of Response (DoR) by RECIST 1.1
Prazo: up to 2 years
|
Duration of response is measured from the date the criterion is first met for CR/PR using RECIST 1.1 rules (whichever is first recorded) until the first date when progressive disease using RECIST 1.1 is documented or death occurred.
|
up to 2 years
|
Progression-Free Survival (PFS) by RECIST 1.1
Prazo: up to 2 years
|
Progression-Free Survival (PFS) is defined as the time from the first dose date of study drug until tumor progression or death, whichever occurs first. A subject who has neither progressed nor died or who progresses or dies after an extended lost-to-follow up time (two or more missed assessments) is censored on the date of last adequate tumor assessment. Subjects without valid baseline or post-baseline tumor assessments are censored on their first dose date. Median and the 2-sided 95% confidence interval (CI) are based on Kaplan-Meier estimate of progression-free survival and time to progression using both observed and censored data. |
up to 2 years
|
Overall Survival (OS) by RECIST 1.1
Prazo: up to 2 years
|
Overall Survival (OS) is measured as the time from the first dose of study drug to death from any cause. Participants who have no death reported are censored at the last contact date the participant is known to be alive. Median and the 2-sided 95% confidence interval (CI) are based on Kaplan-Meier estimate of progression-free survival and time to progression using both observed and censored data. |
up to 2 years
|
Time to Progression (TTP) by RECIST 1.1
Prazo: up to 2 years
|
Time to Progression (TTP) is defined as the time from the first dose date of study drug until tumor progression; TTP does not include death. The censoring rules are the same as PFS except that deaths without progression are censored at last adequate tumor assessment. Median and the 2-sided 95% confidence interval (CI) are based on Kaplan-Meier estimate of progression-free survival and time to progression using both observed and censored data. |
up to 2 years
|
Maximum Observed Concentration (Cmax)
Prazo: 28 days
|
Blood was collected according to intensive and sparse sampling strategies to estimate the population pharmacokinetic (PK) of CC-122 when administered in combination with nivolumab.
|
28 days
|
Area Under the Concentration Time Curve (AUC)
Prazo: 28 days
|
Blood was collected according to intensive and sparse sampling strategies to estimate the population pharmacokinetic (PK) of CC-122 when administered in combination with nivolumab.
|
28 days
|
Time to Maximum Concentration (Tmax)
Prazo: 28 days
|
Blood was collected according to intensive and sparse sampling strategies to estimate the population pharmacokinetic (PK) of CC-122 when administered in combination with nivolumab.
|
28 days
|
Terminal Half-life (T-HALF)
Prazo: 28 days
|
Blood was collected according to intensive and sparse sampling strategies to estimate the population pharmacokinetic (PK) of CC-122 when administered in combination with nivolumab.
|
28 days
|
Apparent Volume of Distribution (Vz/F)
Prazo: 28 days
|
Blood was collected according to intensive and sparse sampling strategies to estimate the population pharmacokinetic (PK) of CC-122 when administered in combination with nivolumab.
|
28 days
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Diretor de estudo: Akshay Patel, Celgene Corporation
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimativa)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Doenças do aparelho digestivo
- Neoplasias por Tipo Histológico
- Neoplasias
- Neoplasias por local
- Adenocarcinoma
- Neoplasias Glandulares e Epiteliais
- Neoplasias do Aparelho Digestivo
- Doenças do Fígado
- Neoplasias Hepáticas
- Carcinoma
- Carcinoma Hepatocelular
- Mecanismos Moleculares de Ação Farmacológica
- Agentes Antineoplásicos
- Agentes Antineoplásicos Imunológicos
- Inibidores de Ponto de Verificação Imunológica
- Nivolumabe
Outros números de identificação do estudo
- CC-122-HCC-002
- 2016-000112-15 (Número EudraCT)
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em Nivolumabe
-
Clinica Universidad de Navarra, Universidad de...Highlight TherapeuticsRecrutamentoCâncer de Pulmão de Células Não Pequenas MetastáticoEspanha
-
Hospices Civils de LyonDesconhecido
-
AHS Cancer Control AlbertaAlberta Cancer FoundationDesconhecido
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)RecrutamentoMesotelioma Pleural Bifásico | Mesotelioma Sarcomatóide PleuralEstados Unidos
-
Institut Claudius RegaudConcluído
-
Akamis BioBristol-Myers SquibbRecrutamentoCâncer metastático | Tumor EpitelialEstados Unidos, Reino Unido
-
Chang Gung Memorial HospitalDesconhecido
-
Fox Chase Cancer CenterHorizon Pharma Ireland, Ltd., Dublin IrelandConcluídoTumores Sólidos AvançadosEstados Unidos
-
Asan Medical CenterAinda não está recrutando
-
Compugen LtdBristol-Myers SquibbAtivo, não recrutandoCâncer de mama | Cancro do ovário | Câncer de pulmão | Câncer de Mama Triplo Negativo | Câncer do endométrio | Câncer Avançado | Câncer colorretal | Neoplasia ovariana | Neoplasia Maligna | Neoplasia pulmonarEstados Unidos